D.M. GADELSHINA, O.N. YASHKINA, O.V. BORISOVA

Samara State Medical University, Samara

  Contact details:

Gadelshina D.M. — postgraduate student of the Department of Pediatric Infections

Address: 89 Chapaevskaya St., Samara, Russian Federation, 443099, tel.: +7-937-796-46-01, e-mail: Dr_Danija@mail.ru

 The pandemic of the new SARS-CoV-2 infection started in 2019 in Wuhan, People’s Republic of China. While in 2019–2020 the incidence of the new coronavirus infection affected mostly people older than 60 y. o. and people with comorbid background, in 2021 the virus spread to the world’s younger population, and in 2022 children of various ages started to be infected.

The purpose is to study the post-COVID syndrome in children, to determine the relationship between clinical manifestations, IgG levels and laboratory parameters in children after the new coronavirus infection.

Material and methods. A clinical study of 180 children aged from 6 to 18 y.o. was conducted. The examined children were divided into 3 groups: 1. Children who had the new coronavirus infection COVID-19, confirmed by PCR diagnostics. 2. Children who had an acute respiratory infection during an increase of the new coronavirus infection, with a negative PCR result for COVID-19. 3. The control group: 60 healthy children without signs of ARI during the COVID increase.

Results. A year after the disease, 21.6% of children had symptoms that could be assessed as manifestations of long-term COVID-19, of which 71% had a positive IgG.

Conclusions. Most children showed a link between clinical manifestations and the level of IgG for the SARS-CoV2 coronavirus, even 6 months after the disease period. Timely examination and differential diagnostics may not only help to diagnose early manifestations, but also to choose a therapy aimed at eliminating these pathological conditions.

Key words: long COVID-19, post-COVID-19 syndrome, children, immunoglobulin G (IgG) class antibodies.

REFERENCES

1. Communicating COVID risks: How the RCCE team is gearing up to develop messages for the next phase of the pandemic. World Health Organization, 2023.
2. WHO Coronavirus (COVID-19) Dashboard. World Health Organization; 2023; Oct.
3. Perego E., 2020, available at: https://twitter.com/elisaperego78/status/1263172084055838721?s=20
4. Munblit D., Buonsenso D., Sigfrid L., Vijverberg S.J.H., Brackel C.L.H. Post-COVID-19 condition in children: a COS is urgently needed. Lancet Respir. Med, 2022, vol. 10 (7), pp. 628–629. DOI: 10.1016/S2213-2600(22)00211-9
5. Say D., Crawford N., McNab S., Wurzel D., Steer A., Tosif S. Post-acute COVID-19 outcomes in children with mild and asymptomatic disease. Lancet Child. Adolesc. Health, 2021, vol. 5 (6), pp. e22-e23. DOI: 10.1016/S2352-4642(21)00124-3
6. Sudre C.H., Murray B., Varsavsky T. et al. Attributes and predictors of long COVID. Nat Med, 2021, vol. 27 (4), pp. 626–631. DOI: 10.1038/s41591-021-01292-y
7. Gomazkov O.A. Post-Covid syndrome: pathophysiology of systemic dysregulations. Uspekhi sovremennoy biologii, 2023, vol. 143, no. 3, pp. 229–238 (in Russ.).
8. Hu B., Guo H., Zhou P., Shi Z.L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol, 2021, vol. 19 (3), pp. 141-154. DOI: 10.1038/s41579-020-00459-7
9. Rubin R. As their numbers grow, COVID-19 “long haulers” stump experts. JAMA, 2020, vol. 324, pp. 1381–1383. DOI: 10.1001/jama.2020.17709
10. Munipalli B., Seim L., Dawson N.L., Knight D., Abu Dabrh A.M. Post-acute sequelae of COVID-19 (PASC): a meta-narrative review of pathophysiology, prevalence, and management. SN Compr. Clin. Med, 2022, vol. 4 (1), pp. 90. DOI: 10.1007/s42399-022-01167-4
11. Proal A.D., van Elzakker M.B. Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms. Front. Microbiol, 2021, vol. 12, 698169. DOI: 10. 3389/fmicb.2021.698169
12. Goërtz Y.M.J., Van Herck M., Delbressine J.M., Vaes A.W., Meys R., Mochado F.V.C. et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res, 2020, vol. 6 (4), 00542-2020 DOI: 10.1183/23120541.00542-2020
13. Tenforde M.W., Kim S.S., Lindsell C.J., Billig R.E. et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network — United States, March-June 2020. MMWR Morb. Mortal. Wkly Rep, 2020, vol. 69 (30), pp. 993–998. DOI: 10.15585/mmwr.mm6930e1
14. Moghimi N., Di Napoli M., Biller J.et al. The Neurological manifestations of post-acute sequelae of SARS-CoV-2 Infection. Curr. Neurol. Neurosci. Rep, 2021, vol. 21 (9), p. 44. DOI: 10.1007/s11910-021-01130-1
15. Martynov A.I., Gorelov A.V., Malyavin A.G. Methodological recommendations “Features of the course of long COVID-19 infection. Therapeutic and rehabilitation measures». Terapiya, 2022, vol. 1 (suppl.), pp. 1–147 (in Russ.). DOI: 10.18565/therapy/2022/Isuppl. 1-147.
16. Nalbandian A., Sehgal K., Gupta A. et al. Post-acute COVID-19 syndrome. Nat. Med, 2021, vol. 27 (4), pp. 601–615. DOI: 10.1038/s41591-021-01283-z
17. COVID-19 disease in children and adolescents: scientific brief. World Health Organization, available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Sci_Brief-Children_and_adolescents-2021.1
18. Carfi A., Bernabei R., Landi F., Gemelli Against COVID-19 post-acute care study group. Persistent symptoms in patients after acute COVID-19. JAMA, 2020, vol. 324 (6), pp. 603–605. DOI: 10.1001/jama.2020.12603
19. Mandal S., Barnett J., Brill S.E., Brown J.S. et al.
20. Zakharova I.N., Osmanov I.M., Tvorogova T.M., Berezhnaya I.V., Makhaeva A.V. Post-Covid syndrome in children in the structure of COVID-19. Pediatriya. Consilium Medicum, 2022, no. 1, pp. 8–14. DOI: 10.26442/26586630.2022.1.201515
21. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Metodicheskie rekomendatsii “Osobennosti klinicheskikh proyavleniy i lecheniya zabolevaniya, vyzvannogo novoy koronavirusnoy infektsiey (COVID-19) u detey. Versiya 2” [Ministry of Health of the Russian Federation. Methodological recommendations “Features of clinical manifestations and treatment of the disease caused by the new coronavirus infection (COVID-19) in children. Version 2″], 2020.
22. Polyakova A.S., Bakradze M.D., Tatochenko V.K., Gadliya D.D. Diagnostic value of determining the level of procalcitonin in the practice of an infectious disease specialist. Voprosy sovremennoy pediatrii, 2017, vol. 16, no. 4, pp. 334–341 (in Russ.). DOI: 10.15690/vsp.v16i4.1781
23. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii. Vremennye metodicheskie rekomendatsii “Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii COVID-19. Versiya 18” [Ministry of Health of the Russian Federation. Temporary guidelines “Prevention, diagnosis and treatment of the new coronavirus infection COVID-19. Version 18″], 2023.
24. RECOVER: researching COVID to enhance recovery. National institutes of health. Researching COVID to Enhance Recovery, 2023.
25. Kopplin N. Garcia A., Reczek A., Wilkinson K. et al. Post-acute sequelae of COVID-19 and longitudinal antibody levels in a community-based cohort. PLoS One, 2023, vol. 18 (9), e0291259. DOI: 10.1371/journal.pone.0291259
26. Brochot E., Demey B., Touze A., Belouzard S. et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front. Microbiol, 2020, vol. 11, 584251. DOI: 10.3389/fmicb.2020.584251
27. Kalyuzhin O.V., Baranova A., Bagaeva M.I. Strategy for managing virus-induced inflammation in COVID-19. Results of a multicenter adaptive randomized double-blind placebo-controlled study in outpatients. Infektsionnye bolezni, 2023, vol. 21, no. 1, pp. 26–34 (in Russ.).